share_log

iBio Inc | 10-K/A: Annual report (Amendment)

SEC ·  Sep 25 04:17

Summary by Futu AI

iBio Inc, a biotechnology company specializing in AI-driven antibody drug discovery, has reported a net loss from continuing operations of approximately $15.4 million, or $4.03 per share, for the fiscal year ended June 30, 2024. This represents a significant reduction from the previous year's net loss of approximately $29.3 million, or $47.88 per share. The company's total operating expenses also decreased to approximately $16.9 million from $29.3 million in the previous year, primarily due to reduced research and development (R&D) and general and administrative (G&A) expenses. iBio's R&D expenses decreased by about 50% to $5.2 million, while G&A expenses fell by 39% to $11.7 million. The company's revenue for the year was reported at $0.2 million, related to research activities and license fees. iBio...Show More
iBio Inc, a biotechnology company specializing in AI-driven antibody drug discovery, has reported a net loss from continuing operations of approximately $15.4 million, or $4.03 per share, for the fiscal year ended June 30, 2024. This represents a significant reduction from the previous year's net loss of approximately $29.3 million, or $47.88 per share. The company's total operating expenses also decreased to approximately $16.9 million from $29.3 million in the previous year, primarily due to reduced research and development (R&D) and general and administrative (G&A) expenses. iBio's R&D expenses decreased by about 50% to $5.2 million, while G&A expenses fell by 39% to $11.7 million. The company's revenue for the year was reported at $0.2 million, related to research activities and license fees. iBio also highlighted its strategic focus on AI and machine learning to advance its preclinical pipeline in immune-oncology and cardiometabolic diseases. The company has not declared any cash dividends on its common stock and has undergone a reverse stock split to improve its stock price. iBio's future plans include leveraging strategic collaborations, advancing in-house programs, and investing in its AI-technology platform to enhance drug discovery and development. The company also completed the sale of its CDMO facility for $8.5 million and settled its obligations with Woodforest, resulting in a more streamlined operation focused on its core mission.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.